A late September order from a Drug Enforcement Administration (DEA) judge to stay the formal hearing process for rescheduling marijuana has driven a significant repricing in prediction markets, with traders scaling back expectations for a swift resolution. The stay, issued on September 29, 2026, by DEA Chief Administrative Law Judge Derek C. Julius, coincided with a sharp drop across all contracts tracking the timeline for a final decision, suggesting the introduction of a new government report has created meaningful procedural delays.
The market reaction was most pronounced in the contract for rescheduling to occur "Before Apr 1, 2027," which fell a steep 79 percentage points to 15% in the sessions following the announcement. This repricing was part of a broader, negative shift across the entire timeline, as all five tracked contracts declined. The move indicates that traders view the judicial stay not as a minor pause but as a substantive roadblock that pushes the likely completion of the rulemaking process further into the future.
Distribution Analysis
The market, which trades on the Kalshi platform, shows a unanimous retreat from earlier timelines. Probabilities for rescheduling in early 2027 have diminished, while contracts for later in the year also saw notable declines, reflecting lowered confidence overall.
| Outcome (Rescheduling Before...) | Current Prob | Change (pp) | Volume (24h) |
|---|---|---|---|
| Before Jan 1, 2027 | 7% | -1.7 | 106 |
| Before Apr 1, 2027 | 15% | -79.0 | 12 |
| Before Jul 1, 2027 | 68% | -8.0 | 17 |
| Before Oct 1, 2027 | 72% | -19.0 | 1 |
| Before Jan 1, 2028 | 67% | -5.0 | 23 |
Net: All 5 tracked contracts declined on 160 total volume, signaling a broad-based pushback of the expected timeline for a final decision.
What's Driving the Shift
The repricing appears directly linked to the new procedural hurdles in the DEA's administrative hearing process, which had been expected to move toward a conclusion.
Procedural Stay Ordered: On September 29, Chief ALJ Julius issued a stay in the rescheduling proceedings. The order pauses the process while the judge considers a motion from parties opposed to rescheduling. This interrupts the expected progression, where the next step was for the ALJ to issue a recommendation to the DEA Administrator based on hearings that concluded in July.
New GAO Report Introduced: The stay was prompted by a motion from groups including DUID Victim Voices to add a new Government Accountability Office (GAO) report to the official record. According to legal analysis, this report, released on September 23, examines federal drug-scheduling procedures and found that both the DEA and FDA lack comprehensive written policies for how they evaluate and schedule controlled substances. Opponents argue this undermines the validity of the current process.
Timeline Uncertainty: The stay requires the government to respond to the motion by October 13, 2026. Judge Julius will then rule on whether to admit the GAO report and allow further briefing. This introduces an indefinite delay, as the ultimate recommendation on rescheduling will remain on hold until the motion is fully resolved. The market's sharp downward move reflects this new, unquantified period of legal and procedural review.
Market Context
The Department of Justice first issued a notice of proposed rulemaking (NPRM) to move marijuana from Schedule I to Schedule III in May 2024. This followed a recommendation from the Department of Health and Human Services (HHS).
The process was intended to be accelerated after President Trump issued Executive Order 14370 in December 2025, directing the Attorney General to complete the rulemaking "in the most expeditious manner." The DEA held formal hearings from June 29 to July 15, 2026 to gather evidence. The current stay represents the most significant delay since those hearings concluded, reversing market expectations of a relatively straightforward path to a final decision.
It is important to note that this rulemaking is distinct from the April 2026 final rule that already rescheduled FDA-approved marijuana drug products and state-licensed medical marijuana to Schedule III. This market concerns the broader rescheduling of all marijuana.
What to Watch
The next key date is October 13, 2026, the deadline for the government and other interested parties to file a response to the motion regarding the GAO report. Following that, Judge Julius's decision on whether to admit the report and lift the stay will be the next major catalyst for the market. A decision to allow further briefing could signal a more prolonged delay, likely pushing probabilities down further, while a quick dismissal of the motion could see them recover.
